Invitae Files for IPO Targeting $86M | GenomeWeb

NEW YORK (GenomeWeb) – San Francisco-based genetic testing company Invitae has filed a prospectus for an initial public offering of its stock for up to $86 million.

Invitae has not priced its shares nor said how many it plans to offer, but said in its Form S-1 filed with the US Securities and Exchange Commission that it plans to trade on the New York Stock Exchange under the symbol "NVTA."

JP Morgan Securities, Cowen and Company, and Leerink Partners are listed as underwriters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.